MMP3 and rheumatoid arthritis: The results of the present study suggest that in RA patients treated with bDMARDs, the serum MMP-3 levels measured at 12 weeks may be useful for the prediction of US remission at 24 weeks after the initiation of iguratimod add-on therapy.